검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | 5-FU + Cisplatin |
Overview Company | ALX Oncology Inc. |
Overview Modality | ANTIBODY |
Overview Target | Metastatic Cancer |
Overview Indication | Metastatic Cancer; Solid Tumor |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
PK/PD Species | Rat |
PK/PD Animal (cat.) | Rat |
PK/PD Experiment | PD |
Toxicology Species | Rat |
Toxicology Animal (cat.) | Rat |
Toxicology Major finding | Combinational studies of BOLD-100/KP1339 with established chemotherapeutics in gastrointestinal multicellular tumor spheroids.. BOLD-100, a ruthenium(III) prodrug also known as KP1339, is currently under clinical investigation for its suitability as a co-therapeutic anticancer drug. Unlike platinum-based chemotherapeutics, it has unique non-DNA targets, mainly GRP78, an enzyme responsible for sign… |
Clinical Primary efficacy | ORR 51.5% |
Clinical ORR | 51.5% |
Clinical PFS | 7.2 |
Clinical OS | 17.2 |
Clinical Result source | ClinicalTrials.gov NCT03777657 |
Clinical Data Tier / Score | A · 54 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 6일 (8일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | 5-FU + Cisplatin |
Overview Company | ALX Oncology Inc. |
Overview Modality | ANTIBODY |
Overview Target | Metastatic Cancer |
Overview Indication | Metastatic Cancer; Solid Tumor |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
PK/PD Species | Rat |
PK/PD Animal (cat.) | Rat |
PK/PD Experiment | PD |
Toxicology Species | Rat |
Toxicology Animal (cat.) | Rat |
Toxicology Major finding | Combinational studies of BOLD-100/KP1339 with established chemotherapeutics in gastrointestinal multicellular tumor spheroids.. BOLD-100, a ruthenium(III) prodrug also known as KP1339, is currently under clinical investigation for its suitability as a co-therapeutic anticancer drug. Unlike platinum-based chemotherapeutics, it has unique non-DNA targets, mainly GRP78, an enzyme responsible for sign… |
Clinical Primary efficacy | ORR 51.5% |
Clinical ORR | 51.5% |
Clinical PFS | 7.2 |
Clinical OS | 17.2 |
Clinical Result source | ClinicalTrials.gov NCT03777657 |
Clinical Data Tier / Score | A · 54 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 6일 (8일 전) |
추천 비교
추천 비교